Note: This document contains side effect information about metreleptin. Some of the dosage forms listed on this page may not apply to the brand name Myalept.
More frequent side effects include: proteinuria and urticaria. See below for a comprehensive list of adverse effects.
Applies to metreleptin: subcutaneous powder for solution
Subcutaneous route (Powder for Solution)
Anti-metreleptin antibodies with neutralizing activity have been identified in patients treated with metreleptin. The consequences are not well characterized but could include inhibition of endogenous leptin action and/or loss of metreleptin efficacy. Severe infection and/or worsening metabolic control have been reported. Test for anti-metreleptin antibodies with neutralizing activity in patients who develop severe infections or show signs suspicious for loss of metreleptin efficacy during treatment. T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with metreleptin. Carefully consider the benefits and risks of treatment with metreleptin in patients with significant hematologic abnormalities and/or acquired generalized lipodystrophy. Metreleptin is available only through a restricted program called the Myalept(TM) REMS Program.
Along with its needed effects, metreleptin (the active ingredient contained in Myalept) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking metreleptin:
Some side effects of metreleptin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to metreleptin: subcutaneous powder for injection
The most frequently reported side effects were headache, hypoglycemia, decreased weight, and abdominal pain.
Very common (10% or more): Hypoglycemia (13%), decreased weight (13%)
Very common (10% or more): Headache (13%)
Common (1% to 10%): Dizziness, paresthesia
Very common (10% or more): Abdominal pain (10%)
Common (1% to 10%): Nausea, diarrhea, pancreatitis
It has been reported that two patients (4%) had symptoms of pancreatitis. Both had a medical history of pancreatitis.
Frequency not reported: Autoimmune disorder, immunogenicity
In vitro neutralizing activity anti-metreleptin antibodies were identified in 2 patients (n=33) with generalized lipodystrophy who showed severe infections and worsening metabolic control (increases in HbA1c and/or triglycerides). Three patients with anti-metreleptin antibodies without lipodystrophy showed excessive weight gain, and/or development of glucose intolerance or diabetes.
In clinical trials, anti-metreleptin antibodies were detected in 36 of 43 generalized lipodystrophy patients, with titers ranging from 1:5 to 1:1,953, 125; however, these numbers may be misleading as detection of antibody formation is highly dependent on the sensitivity and specificity of the assay (the assays utilized in clinical trials lacked sensitivity), handling of the sample, concomitant drugs, and underlying disease. Due to incompleteness of the immunogenicity data, the clinical significance and the magnitude and persistence of the anti-drug responses are not well characterized.
Common (1% to 10%): Ovarian cyst
Common (1% to 10%): Anemia
Common (1% to 10%): Injection-site erythema, urticaria
Frequency not reported: Generalized rash
Common (1% to 10%): Arthralgia, back pain
Common (1% to 10%): Pyrexia, ear infection, fatigue
Common (1% to 10%): Proteinuria
Common (1% to 10%): Upper respiratory tract infection
Three cases of T-cell lymphoma were reported among patients with acquired generalized lipodystrophy; 2 patients diagnosed with peripheral T-cell lymphoma during treatment had immunodeficiency and significant hematologic abnormalities including severe bone marrow abnormalities prior to starting treatment. Anaplastic large cell lymphoma was reported in 1 patient receiving this drug who did not have hematologic abnormalities before treatment.
Frequency not reported: T-cell lymphoma, anaplastic large cell lymphoma
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Myalept